life scienc tool diagnost
ep top consensu ep beat
estim stronger revenu profit note adjust
guidanc midpoint vs consensu
fulli reflect latest ep upsid off-set increment fx tariff
headwind consequ rais ep
aforement factor rais tp
encourag core strength across busi line
except dental/envista dental ipo track
revenu profit exceed plan organ revenu nice
ahead strength life scienc vs estimate
diagnost vs dynam continu
dental disappoint vs flat trend anem albeit
tougher comp note lighter sale tradit consum
rose line plan gross margin fell bp bp plan
howev lower administr expens bp bp plan help
off-set ebitda margin degrad bp albeit bp plan
billion fcf/ni convers help fund million
share may grind higher share ytd vs
view share may move higher latest upsid across
relev busi segment said await greater disclosur
latest well futur perform certain intern market
name underli core growth china well greater detail fx
tariff dynam balanc year key topic broader life
scienc univers question call ge/dent spin updat end-
market demand trend particularli biopharma/china upside/downsid
guidanc risk util macro condit miscu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lead manufactur system instrument
consum broad array purpos custom
diagnost dental environment health/appli scienc
price jul rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
acceler key end market global signific rebound
dental trend better expect implement db
acquir compani market share gain materi margin
grey sky scenario base signific weak
key end market prolong weak dental demand trend
deceler core growth acquisit integr headwind
compani mention price
